[{"PropertyPlantAndEquipmentNet_0_Q2_USD":26272000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":4011000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":24000.0,"FinanceLeaseInterestPaymentOnLiability_2_Q2_USD":63000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-281594000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":36000.0,"InterestPaidNet_2_Q2_USD":10814000.0,"RestrictedCashCurrent_0_Q2_USD":176000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q2_USD":-5726000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2_Q2_USD":-13729000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"RepaymentsOfLongTermDebt_2_Q2_USD":18108000.0,"DueFromRelatedPartiesCurrent_0_Q2_USD":8962000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":146754299.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":142713463.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q2_USD":-5726000.0,"NetIncomeLossAttributableToNoncontrollingInterest_2_Q2_USD":-13729000.0,"MarketableSecuritiesCurrent_0_Q2_USD":459243000.0,"AssetsCurrent_0_Q2_USD":909871000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-7206000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_0_Q2_USD":1500000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":91377000.0,"Assets_0_Q2_USD":1081486000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":775594000.0,"CommonStockSharesIssued_0_Q2_shares":152894108.0,"FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":151000.0,"FinanceLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":275000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":4287000.0,"InterestExpenseDebtExcludingAmortization_1_Q2_USD":7642000.0,"InterestExpenseDebtExcludingAmortization_2_Q2_USD":14023000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"TreasuryStockValue_0_Q2_USD":130308000.0,"FinanceLeaseInterestExpense_2_Q2_USD":56000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":38903476.0,"TreasuryStockShares_0_Q2_shares":3279368.0,"FinanceLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":432000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":109000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":109000.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":1412000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":45970000.0,"FinanceLeaseInterestExpense_1_Q2_USD":28000.0,"ShareBasedCompensation_2_Q2_USD":63689000.0,"OperatingLeaseLiability_0_Q2_USD":22562000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-156000.0,"TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_0_Q2_USD":1865000.0,"CommonStockValue_0_Q2_USD":153000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_0_Q2_USD":1500000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"AccountsReceivableNetCurrent_0_Q2_USD":1213000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":2457000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":8223000.0,"ProceedsFromStockPlans_2_Q2_USD":1652000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":22000.0,"MinorityInterest_0_Q2_USD":6804000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":26840000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":101960000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":224519000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":2783000.0,"IncreaseDecreaseInDueFromRelatedParties_2_Q2_USD":8962000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":6378000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_0_Q2_USD":1500000.0,"TreasuryStockValueAcquiredCostMethod_1_Q2_USD":5308000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":4052000.0,"IncreaseDecreaseInEmployeeRelatedLiabilities_2_Q2_USD":-8494000.0,"FinanceLeaseLiability_0_Q2_USD":1670000.0,"Liabilities_0_Q2_USD":1537111000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":799679000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":18022000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":378420000.0,"OtherAssetsNoncurrent_0_Q2_USD":49797000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":13025000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-96255000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":93000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-259583000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-259427000.0,"FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":420000.0,"FinanceLeaseLiabilityPaymentsDue_0_Q2_USD":1945000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":238934000.0,"CostsAndExpenses_1_Q2_USD":148039000.0,"CostsAndExpenses_2_Q2_USD":316005000.0,"MinorityInterestPeriodIncreaseDecrease_1_Q2_USD":3618000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":546521000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-96348000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":-101981000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":15964000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"LiabilitiesCurrent_0_Q2_USD":131909000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":5360000.0,"MarketableSecuritiesNoncurrent_0_Q2_USD":60688000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-242478000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":32509000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":3302000.0,"FinanceLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0662,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":60000.0,"AmortizationOfFinancingCosts_1_Q2_USD":24000.0,"AmortizationOfFinancingCosts_2_Q2_USD":47000.0,"PaymentsToAcquireEquityMethodInvestments_2_Q2_USD":20000000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":509934000.0,"RestrictedCashNoncurrent_0_Q2_USD":2532000.0,"CommonStockSharesOutstanding_0_Q2_shares":149614740.0,"ProceedsFromConvertibleDebt_2_Q2_USD":747500000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":1040000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":22449000.0,"AccountsPayableCurrent_0_Q2_USD":22329000.0,"PaymentsOfDebtIssuanceCosts_2_Q2_USD":16064000.0,"NonoperatingIncomeExpense_2_Q2_USD":-11637000.0,"NonoperatingIncomeExpense_1_Q2_USD":-8059000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_2_Q2_USD":0.0,"OperatingLeasePayments_2_Q2_USD":2858000.0,"ProceedsFromDebtNetOfIssuanceCosts_2_Q2_USD":25000000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":-457490000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":381128000.0,"FinanceLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":459000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":5723000.0,"PaymentsForTenantImprovements_2_Q2_USD":2136000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0579,"InterestExpenseDebt_1_Q2_USD":8509000.0,"InterestExpenseDebt_2_Q2_USD":15610000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":21177000.0,"LongTermDebtNoncurrent_0_Q2_USD":102611000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":11216000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":26670000.0,"InterestExpense_1_Q2_USD":10839000.0,"InterestExpense_2_Q2_USD":20577000.0,"FinanceLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":445000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"LeaseCost_1_Q2_USD":2341000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1133854000.0,"PreferredStockSharesAuthorized_0_Q2_shares":25000000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":21865000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":1081486000.0,"OperatingLeaseCost_1_Q2_USD":1256000.0,"OperatingLeaseCost_2_Q2_USD":2621000.0,"PreferredStockValue_0_Q2_USD":null,"InvestmentIncomeInterest_1_Q2_USD":323000.0,"InvestmentIncomeInterest_2_Q2_USD":717000.0,"PaymentsForRepurchaseOfCommonStock_2_Q2_USD":55308000.0,"OperatingIncomeLoss_1_Q2_USD":-94015000.0,"OperatingIncomeLoss_2_Q2_USD":-261519000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":54024000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":54486000.0,"CommonStockSharesAuthorized_0_Q2_shares":500000000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-1400000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":3980000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":4278000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":66931000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":32035000.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":1540000.0,"AmortizationOfDebtDiscountPremium_1_Q2_USD":843000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_0_Q2_USD":1500000.0,"VariableLeaseCost_1_Q2_USD":969000.0,"VariableLeaseCost_2_Q2_USD":1720000.0,"IntangibleAssetsNetIncludingGoodwill_0_Q2_USD":20000000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":775558000.0,"AccretionExpense_2_Q2_USD":2653000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":4248000.0,"StockholdersEquity_0_Q2_USD":-464294000.0,"LeaseCost_2_Q2_USD":4514000.0,"FinanceLeaseLiabilityCurrent_0_Q2_USD":258000.0,"ProfitLoss_1_Q2_USD":-102074000.0,"ProfitLoss_2_Q2_USD":-273156000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.66,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.82,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":4041000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":2599000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q2_USD":900000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":4540000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":13265000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":-273312000.0,"Ticker":"BBIO","CIK":"1743881","name":"BRIDGEBIO PHARMA, INC.","OfficialName":"BridgeBio Pharma Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1594164456.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210805"}]